CONTEMPORARY REVIEW

Vascular Smooth Muscle Cells in Aortic Aneurysm: From Genetics to Mechanisms

Haocheng Lu, PhD; Wa Du, PhD; Lu Ren, PhD; Milton H. Hamblin, PhD; Richard C. Becker, MD; Y. Eugene Chen, MD, PhD; Yanbo Fan, MD, PhD

ABSTRACT: Aortic aneurysm, including thoracic aortic aneurysm and abdominal aortic aneurysm, is the second most prevalent aortic disease following atherosclerosis, representing the ninth-leading cause of death globally. Open surgery and endovascular procedures are the major treatments for aortic aneurysm. Typically, thoracic aortic aneurysm has a more robust genetic background than abdominal aortic aneurysm. Abdominal aortic aneurysm shares many features with thoracic aortic aneurysm, including loss of vascular smooth muscle cells (VSMCs), extracellular matrix degradation and inflammation. Although there are limitations to perfectly recapitulating all features of human aortic aneurysm, experimental models provide valuable tools to understand the molecular mechanisms and test novel therapies before human clinical trials. Among the cell types involved in aortic aneurysm development, VSMC dysfunction correlates with loss of aortic wall structural integrity. Here, we discuss the role of VSMCs in aortic aneurysm development. The loss of VSMCs, VSMC phenotypic switching, secretion of inflammatory cytokines, increased matrix metalloproteinase activity, elevated reactive oxygen species, defective autophagy, and increased senescence contribute to aortic aneurysm development. Further studies on aortic aneurysm pathogenesis and elucidation of the underlying signaling pathways are necessary to identify more novel targets for treating this prevalent and clinical impactful disease.

Key Words: aortic aneurysm ■ genetics ■ mechanism ■ vascular smooth muscle cell

Aortic aneurysm is characterized by a permanent increase in the diameter of the aorta (>50% increase). Aortic aneurysm is the second most prevalent aortic disease following atherosclerosis and accounts for the ninth-leading cause of death overall.1 The estimated incidence is 2.79 per 100,000 individuals.2 Although an aortic aneurysm can remain asymptomatic for a long time, sudden rupture leads to life-threatening hemorrhage with a high mortality rate.1

The aorta is divided into the thoracic aorta (including the aorta root, ascending aorta, aortic arch, and descending thoracic aorta) and abdominal aorta (suprarenal aorta and infrarenal aorta). Aortic aneurysm can occur in the thoracic aorta (thoracic aortic aneurysm [TAA]) or abdominal aorta (abdominal aortic aneurysm [AAA]). The prevalence of AAA is about 3 times that of TAA.1 TAA and AAA share many similarities but also have distinct features. In this review, we summarize recent advancements in aortic aneurysm and mainly focus on the role of vascular smooth muscle cells (VSMCs) in this severe disease.

PATHOGENESIS OF AORTIC ANEURYSM

The aorta can be divided into 3 layers: intima, media, and adventitia. The intima consists of an endothelium that supports the internal elastic lamina. A smooth and healthy endothelial layer is critical for the aorta to maintain an anti-inflammatory and antithrombosis phenotype.3 The media is composed of several layers of VSMCs and surrounding elastic and connective tissue. The adventitia is the connective tissue surrounding the external elastic lamina to anchor the vessel and provide blood supply.4 Aortic aneurysm takes place...
through progressive weakening of the aortic wall, which involves all 3 layers. Aortic dissection is caused by tearing of the intima and media, resulting in blood entering the space between the media and adventitia. Although the pathogenesis of aortic aneurysm remains to be fully elucidated, the development of this vascular disease is highlighted by prominent inflammation, gradual loss of VSMCs, and disruption of the extracellular matrix (ECM) (Figure 1). Here, we summarize the current well-recognized theories/pathways of aortic aneurysm pathogenesis.

Genetic Risk Factors in Aortic Aneurysm

Both TAA and AAA have genetic risk factors. Typically, TAA has a more robust genetic background than AAA. About 20% of patients with TAA inherit risk mutations, while patients with AAA typically do not exhibit this pattern. AAA shares many features with TAA, including VSMC death, ECM degradation, and inflammation. However, the pathophysiology of AAA development is distinct in many respects. The difference in pathogenesis between TAA and AAA could be attributed to their embryological origins. VSMCs in the ascending aorta are derived from neural crest stem cells and progenitor cells in the second heart field, while VSMCs in the descending aorta are derived from somites. This difference in developmental origin could also lead to the distinctive transcriptomic profiles in aortic VSMCs. Linkage analysis and genome-wide association studies have provided insightful genetic information about the etiology of AAA. A linkage study performed in 2004 identified 2 susceptible loci for AAA in the regions 19q13 and 4q13. Large scale genome-wide association studies have identified several risk loci including rs10985349 (DAB2 interacting protein), rs1466535 (low-density lipoprotein receptor-related protein 1), rs6511720 (low-density lipoprotein receptor [LDLR]), rs602633 (sortilin-1), rs4129267 (interleukin-6 receptor), rs10757274 (CDKN2BAS1/ANRIL [9p21]), rs1795061 (SET and MYND domain containing 2), rs9316871 (LINC00540), rs3827066 (PCF11/MMP9/ZNF335), and rs2836411 (ETS Transcription Factor ERG). Intriguingly, AAA risk loci overlap with several atherosclerosis risk loci, including 9p21, sortilin-1, and low-density lipoprotein receptor. These findings suggest that AAA and atherosclerosis share common pathways during disease development.

Transforming growth factor-β (TGF-β) signaling is one of the most studied signaling pathways that play pivotal roles in vascular development and maintenance. Mutations in TGF-β signaling pathway-related genes (TGF-β receptor 1/2, SMAD2/3, or TGFBR2/3) are associated with TAA formation in heritable connective tissue disorders, including Loeys-Dietz and Marfan syndromes, highlighting its importance in TAA development. TGF-β has pleiotropic effects on different cell types in the body. Three highly conserved isoforms of TGF-β exist in humans: TGF-β1, TGF-β2, and TGF-β3. They share a common receptor and downstream pathway, although they have distinct tissue distribution. TGF-β binds to TGF-βR1 and TGF-βR2 and facilitates phosphorylation and subsequent activation. Downstream TGF-β receptor signaling can be divided into 2 different pathways, a SMAD-dependent pathway and a SMAD-independent noncanonical pathway. The role of the TGF-β pathway in both TAA and AAA is still controversial, as the knockout of different genes and different intervention methods (knockout or neutralizing antibody) give different results. It could be that TGF-β has multiple downstream pathways (canonical versus noncanonical pathway) and may play different roles in different cell types and at various disease stages. These controversial results increase the difficulty of developing TGF-β-based therapy for aortic aneurysm. The recent advancement of genetic studies in TAA and AAA has been well summarized in other publications.

Inflammation in Aortic Aneurysm

Inflammation is a hallmark of aneurysm development, although it has been more extensively studied in AAA. Accumulating studies on AAA in both human samples and mouse models indicate that inflammation is a necessary process underlying AAA. Samples from patients with AAA show massive inflammatory cell infiltration. Both innate immune cells (mast cells, macrophages, and neutrophils) and adaptive immune cells (dendritic cells, B cells, and T cells) have been shown to be related to AAA. Neutrophil infiltration occurs in the early phase of AAA development, and neutrophils are important sources of matrix metalloproteinase (MMP)-2 and MMP-9. Depleting neutrophils by an antineutrophil antibody or inhibition of neutrophil recruitment by intraperitoneal injection of a neutralizing antibody against...
Family with sequence similarity 3, member D16 reduces AAA formation in the elastase mouse model, underscore the importance of neutrophils in AAA development. Monocytes are recruited into the aortic wall by chemotactic cytokines, including C-C motif chemokine ligand 2 and interleukin-17 during AAA development. In both human and mouse AAA lesions, macrophages produce MMPs, cytokines, and chemokines. In addition, macrophages also exert reparative functions in the aortic wall. As aortic aneurysms evolve, LY6C low monocytes or segregated-nucleus-containing atypical monocytes with reparative potential are recruited to the lesions and exhibit anti-inflammatory and pro-resolving effects to strengthen aortic wall integrity. The role of macrophages in AAA has been nicely reviewed and will not be discussed in detail here.

In TAA development, the role of inflammation is less well studied. In a mouse thoracic aortic dissection model (β-aminopropionitrile+angiotensin II), neutrophil depletion by an anti-Gr-1 antibody decreases the dissection incidence, indicating that neutrophils promote TAA development. Interleukin-6 is also elevated in human patients with TAA, and interleukin-6 knock-out inhibits elastase-induced TAA in C57BL/6 mice. In summary, inflammation representing a critical response to vascular injury is an essential component for aortic aneurysm development and progression. A deeper understanding of this process will help to identify novel potential therapeutic targets for aortic aneurysm treatment.

### ECM Disruption in Aortic Aneurysm

As a critical component of the healthy vascular wall, the ECM is synthesized and secreted by different vascular cell types, including VSMCs, endothelial cells and fibroblasts. The aortic ECM mainly consists of collagen, elastin, proteoglycans, and glycoproteins, providing the aorta with the expansion capacity and tensile strength. Besides this mechanical function, the ECM also modulates VSMC proliferation, adhesion, and migration. The balance among synthesis, deposition, and degradation maintains ECM homeostasis. The critical role of ECM disruption was revealed by the impact of ECM-related protein mutations on TAA development. ECM degradation is mediated by various proteinases, including MMPs, cathepsins, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinase with thrombospondin motifs. In total, 23 different MMPs have been discovered and can be divided into collagenases, matrilysins, gelatinases, stromelysins, and membrane-type MMPs. Tissue inhibitors of metalloproteinase directly bind to and inhibit different groups of MMPs in the vascular wall. In both TAA and AAA, MMPs play a pivotal role in ECM remodeling. In the circumstance of aortic aneurysm, besides VSMCs, endothelial cells, and fibroblasts, infiltrated...
immune cells secrete additional MMPs that further aggravate extracellular matrix degradation. Overall, the imbalance between ECM proteases and protease inhibitors leads to the development of aortic aneurysm.

**ANIMAL MODELS FOR MECHANISM STUDIES**

Animal models provide valuable tools to understand disease mechanisms and test novel therapies before clinical trials. There have been multiple animal models developed to study aortic aneurysm in vivo. Although animal models cannot perfectly recapitulate all the features of human disease, they are still useful in testing scientific hypotheses. We have incorporated a comparison among different animal models in Figure 2.

**Angiotensin II Infusion**

Angiotensin II plus hyperlipidemia is the most commonly used aneurysm model. This model uses a combination of continuous infusion of angiotensin II by subcutaneous implantation of osmotic pumps and hyperlipidemia by Apoe or Ldlr knockout or an adeno-associated viral vector expressing a gain-of-function mutation (D377Y) of mouse proprotein convertase subtilisin/kexin type 9 in C57BL/6 mice. This model is technically easy to achieve without any sophisticated surgery skills. The aortic aneurysm usually appears in the suprarenal region, and dissection and hemorrhage can also be seen in the aortic root. The model shows several essential features of human AAA, including atherosclerosis, medial degeneration, intramural thrombosis, leukocyte infiltration, and dissection. However, the location of AAA in this experimental model is not consistent with human AAA, which occurs more often in the infrarenal region.

**Mineralocorticoid Receptor Agonists Plus Salt**

In this mouse model, the combination of deoxycorticosterone acetate and salt or aldosterone and salt can induce a high incidence of aortic aneurysm and an aortic aneurysm may occur in both thoracic and abdominal aortas. Pathological changes are similar to the angiotensin II model, except that atherosclerosis is not present in this mouse model.

**Elastase Model**

The elastase-induced AAA model consists of application of porcine pancreatic elastase either in the lumen or outside adventitia. This model does not require a specific genetic background and can be used in both mice and rats. Unlike the angiotensin II model, aortic dissection is not seen in this model and rupture is also uncommon. This model is primarily driven by ECM degeneration and massive calcification.

---

**Figure 2. Comparison of animal models used for aortic aneurysm studies.**

Animal models have been developed to recapitulate features of human aortic aneurysms. Aortic aneurysms in rodent species can be induced by several methods, including surgical procedures, pharmacological treatments, and genetic manipulations. Each model has its advantages and drawbacks when comparing with human aortic aneurysm pathology. AAA indicates abdominal aortic aneurysm; AngII, angiotensin II; BAPN, β-aminopropionitrile; ILT, intraluminal thrombus; IMT, intramural thrombus; MCR, mineralocorticoid receptor; and TAA, thoracic aortic aneurysm.
leukocyte infiltration. The limitation of this model is that atherosclerosis and intramural thrombus are not present. In addition, the severity of the aneurysm is highly dependent on the porcine pancreatic elastase batch. The elastase model has recently been employed in TAA studies by the placement of elastase on the thoracic aortic wall, further expanding this model’s usage.

**CaCl₂ Model**
This procedure is performed by applying cotton gauze soaked with CaCl₂ to the aortic wall, then adding phosphate-buffered saline on the aorta. CaPO₄ precipitation in the aortic wall was considered the driver for AAA formation. The pathology of this model shows calcification, elastin breakdown, VSMC loss and leukocyte infiltration, but rupture, intramural thrombus, or atherosclerosis does not occur.

**β-Aminopropionitrile Model**
Lysyl-oxidase (LOX) is an enzyme secreted by VSMCs and performs the crosslinking between collagens. Loss-of-function mutation of LOX leads to TAA and dissection in humans. β-Aminopropionitrile, a potent inhibitor of LOX, combined with angiotensin II or deoxycorticosterone acetate, induces a high incidence of both TAA and AAA. In this model, aneurysm incidence can reach 100%, and rupture is frequent. Histological studies indicate elastic fiber breaks, thrombus formation, and leukocyte infiltration.

**Large-Animal Models**
Large animals are more expensive than small animals (mice or rats), but they are useful to test endovascular devices or surgical procedures. There are several different ways to generate aneurysm models in large animals: (1) aortic patch and artificial aneurysm graft; (2) intra-aortic porcine pancreatic elastase infusion; and (3) aortic dissection with endovascular procedures. Many drugs effectively preventing aortic aneurysm in animal models did not show protective effects in clinical trials. This inconsistency could partially attribute to the limitations of animal models in recapitulating human disease. Better understanding of the pathogenesis of aortic aneurysm is the key to lead to effective therapies.

## ROLE OF VSMCS IN AORTIC ANEURYSM
The loss of organized structure of the aorta leads to a weakened vessel and subsequent dilatation of the aorta. Although other cell types, including endothelial cells, neutrophils, macrophages, and lymphocytes, are involved in aortic aneurysm development, VSMC dysfunction is crucial for the loss of structural integrity in the aortic wall. VSMC apoptosis and ECM degeneration are the hallmarks of aortic aneurysm. Here, we mainly focus on discussing the role of VSMCs in aortic aneurysm (Figure 3).

### Phenotypical Switching and Reprogramming of VSMCs
Healthy VSMCs maintain a quiescent and contractile phenotype, but they switch to a proliferative, synthetic, and migratory phenotype in response to various pathological stimuli. The phenotypic switching of VSMCs has been studied extensively in atherosclerosis. Transcription of contractile genes (transgelin, Calponin 1 and actin alpha 2 smooth muscle) is mainly controlled by myocardin along with serum response factor. On the contrary, Krüppel-like factor 4 is a critical transcription factor promoting VSMC phenotypic switching from a contractile to synthetic phenotype through several mechanisms, including by directly binding to G/C repressor elements and by inhibiting serum response factor binding to CArG-boxes in the target gene promoter. In addition, epigenetic regulation and chromatin remodeling also participate in the VSMC phenotypic switching. For example, H3K4 dimethylation, H4 acetylation, H3K79 dimethylation, and H3K9 acetylation are required for the myocardin- serum response factor complex to access the promoter of VSMC-specific markers and contractile genes. Treating VSMCs with dedifferentiating stimuli (platelet-derived growth factor-BB, injury, oxidized phospholipids) removes these histone modifications, leading to transcriptional suppression of these VSMC-specific genes. The phenotypic switching of VSMCs has also been documented in both TAA and AAA development. Phenotypic modulation takes place in early aneurysm development in both human aneurysm samples and mouse models. Recently, VSMC clonal expansion was observed in angiotensin II–induced aortic aneurysm by using Myh11-CreERT2/Rosa26 Confetti mice. Proliferative VSMCs showed a decreased expression of smooth muscle cell (SMC) markers and increased expression of phagocytic markers. In summary, VSMC phenotypic switching leads to vascular dysfunction and contributes to the pathogenesis of aneurysm formation.

In recent years, single-cell RNA sequencing has expanded the toolbox to understand cell heterogeneity in complex tissues. In a Marfan syndrome mouse model (Fbn1<sup>C1039G/+</sup>), single-cell RNA sequencing combined with an SMC lineage tracing study has shown a specific SMC population in the diseased aorta marked by decreased expression...
of SMC markers (myosin heavy chain 11 and actin alpha 2 smooth muscle), increased ECM synthesis (collagen type I alpha 1 chain and lumican), elevated dedifferentiation (Krüppel-like factor 4, and increased proliferation. A different aortic aneurysm mouse model (hypercholesterolemia+Tgfrb2 ablation), a similar strategy was used, and the results demonstrated that in aortic aneurysm formation, a subset of VSMCs transform to mesenchymal-like stem cells and then give rise to various types of cells, including adipocytes, chondrocytes, osteoblasts, and macrophage-like cells. This process is dependent on Krüppel-like factor 4, as Klf4 knockout largely abrogates aortic aneurysm development in mice. Maintaining the contractile force of VSMCs is essential for aortic function and structure. The implication of force generation in the development of TAA is evidenced by genome-wide association studies showing that mutations of genes encoding filaments (actin alpha 2 smooth muscle and myosin heavy chain 11), kinases (myosin light chain kinase and protein kinase cGMP-dependent 1), ECM glycoproteins (LOX, fibrillin 1, or microfibrillar-associated protein 5) are associated with TAA. Thus, disruption of VSMC force generation would lead to TAA and aortic dissection.

**Inflammation and MMPs in VSMCs**

Similar to atherosclerosis, inflammation is always present in the aneurysmal lesion as an immune response to vascular injury. VSMCs can secrete multiple cytokines (interleukin-6, monocyte chemoattractant protein-1, interleukin-1β, and tumor necrosis factor-alpha) and activate inflammatory pathways, including the nuclear factor kappa B (NF-κB) and the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathways. These pathways are involved in the regulation of MMPs, which play a crucial role in the remodeling of the ECM and the progression of aortic aneurysms.

**Figure 3. The role of VSMCs in aortic aneurysms.**

VSMCs play a critical role in the development of an aortic aneurysm. In pathological conditions, VSMCs undergo phenotypic switching, cell death (apoptosis and necroptosis), oxidative stress, inflammation, senescence, and insufficient autophagy, contributing to aortic aneurysm development. Critical signaling pathways have been identified to mediate VSMC dysfunction in aortic aneurysms. The schematic illustration also shows the genes/pathways either decreased/inactivated (blue) or increased/activated (red) in aortic aneurysm development. ARHGAP18 indicates Rho GTPase activating protein 18; AT1R, angiotensin II receptor type 1; AT2R, angiotensin II receptor type 2; ATG5, autophagy related 5; ATG7, autophagy related 7; BCL2, B-cell lymphoma 2; CCN3, cellular communication network factor 3; ERK1/2, extracellular signal-regulated kinases 1/2; iNOS, inducible nitric oxide synthase; JAK, Janus kinase; KLF4, Krüppel like factor 4; mTOR, mammalian target of rapamycin; MYOD, myocardin; NAMPT, nicotinamide phosphoribosyltransferase; NF-κB, nuclear factor kappa B; NOX4, nicotinamide adenine dinucleotide phosphate oxidase 4; Nrf2, nuclear factor erythroid 2-related factor 2; PPARγ, peroxisome proliferator-activated receptor-gamma; RIP1/3, receptor interacting serine/threonine kinase 1/3; SIRT1, sirtuin1; SRF, serum response factor; STAT, signal transducer and activator of transcription; and TFEB, transcription factor EB.
factor-α) and chemotactic factors to recruit inflammatory cells to the aortic wall. Multiple signaling pathways, including Janus kinase–signal transducer and activator of transcription, mammalian target of rapamycin, nicotinamide adenine dinucleotide phosphate oxidase 4, nuclear factor kappa B, switch/sucrose nonfermentable–related, matrix-associated, actin-dependent regulator of chromatin, subfamily d, member 1, extracellular signal-regulated kinases 1/2, and Rho kinase promote VSMC inflammation activated by macrophage-derived netrin-1 and pro-oxidative oxidative stress promotes AAA development via reducing VSMC apoptosis in the angiotensin II mouse. 

Several MMPs from VSMCs are implicated in the development of aortic aneurysm. MMP-2 and MMP-9 are the most studied MMPs produced by VSMCs. MMP-2 is constitutively expressed in VSMCs, while MMP-9 expression is inflammation inducible. Transcriptome analysis of VSMCs isolated from human AAA samples shows increased MMP-2 and MMP-9, which can further be augmented by recruited macrophages. The increases in MMP-2 and MMP-9 contribute to ECM degeneration in the aortic wall. Besides MMP-2 and MMP-9, VSMC-derived MMP-3 can be activated by macrophage-derived netrin-1 and promotes AAA formation in mice. Thus, it is critical to restore the balance between ECM proteases and protease inhibitors in VSMCs to inhibit aortic aneurysm formation and progression.

Oxidative Stress in VSMCs

Oxidative stress is high in plasma and aneurysmal segments from subjects with AAA. Reactive oxygen species (ROS) contribute to AAA development by influencing VSMC inflammation, MMP activation, and apoptosis. Antioxidants including vitamin E, edaravone, ursodeoxycholic acid, lipoic acid, apocynin, and folic acid inhibit VSMC apoptosis in mice. Consistent with pharmacological inhibition, genetically engineered transgenic mouse models demonstrated that excessive oxidative stress promotes AAA development. Nicotinamide adenine dinucleotide phosphate oxidases produce ROS in cells. Deletion of the nicotinamide adenine dinucleotide phosphate oxidase subunit, \( p47^\text{phox} \) attenuates angiotensin II–induced AAA in Apoe\(^{-} \) mice. Inducible nitric oxide synthase deletion reduces ROS and inhibits CaCl\(_2\)-induced AAA. On the other hand, catalase (a critical H\(_2\)O\(_2\) scavenger) overexpression in VSMCs protects against AAA induced by either angiotensin II or CaCl\(_2\) in mice. ROS is also elevated during TAA development. VSMCs from Loeys-Dietz or Marfan syndrome mice exhibited reduced mitochondrial respiration and an increased ROS level. Nox4 deletion ameliorates aortic root dilatation in Marfan syndrome (Fbn1\(^{C1039G/+}\)) mice. Although the actual mechanisms of how ROS is generated and how ROS affects VSMC biology are not fully clear, it is well recognized that excessive ROS leads to VSMC dysfunction and subsequent aortic wall disruption in aortic aneurysm development.

VSMC Loss in Aortic Aneurysm

The loss of VSMCs is a common phenomenon in aneurysmal lesions, where VSMC death may occur through multiple signaling pathways. The elucidation of these pathways can help us develop drugs targeting VSMCs to maintain normal VSMC population and function in the diseased aorta.

Apoptosis

Apoptosis is mediated by 2 distinct pathways, the intrinsic pathway (mitochondria mediated) and extrinsic pathway (death receptor mediated). Apoptosis is critical for body homeostasis by removing dysfunctional or senescent cells. However, excessive VSMC apoptosis during human and mouse aortic aneurysm development results in weakening of the aortic wall. VSMC apoptosis could be induced by excessive ROS, cytokines, or modified lipoproteins. In Marfan syndrome, angiotensin II can induce VSMC apoptosis via angiotensin II receptor types 1 and 2. Using an in vitro Marfan syndrome vascular cell model derived from human induced pluripotent stem cells, inhibition of the p38 pathway and Krüppel-like factor 4 knockdown were found to reduce SMC apoptosis.

Based on these findings, inhibition of VSMC apoptosis has been shown to be effective in preventing aortic aneurysm in murine models. 2-Hydroxypropyl-beta-cyclodextrin inhibits AAA development in both \( \beta \)-aminopropionitrile and angiotensin II–induced AAA via upregulation of B-cell lymphoma 2 in a transcription factor EB–dependent manner. KMUP-3, a xanthine derivative, suppresses VSMC apoptosis in the angiotensin II–induced AAA model. A recent study revealed that APLN-NMeLeu9-A2, an apelin analog, prevented angiotensin II–induced AAA formation via reducing VSMC apoptosis in \( \text{Ldlr}^-\) knockout mice on a high-fat diet. Moreover, deletion of cyclin-dependent kinase inhibitor 2B (\( \text{Cdkn2b} \)), a tumor suppressor gene, promotes p53-dependent VSMC apoptosis and induces larger aortic aneurysms in the AAA elastase mouse model. The pan-caspase inhibitor Q-VD-OPh diminished VSMC apoptosis, inflammation, and AAA formation in the angiotensin II mouse.
model. Although apoptosis is the cause of VSMC loss in aortic aneurysm, it is still challenging to target apoptosis as a potential treatment because apoptosis itself has important homeostatic functions that are necessary to maintain proper function and vascular health. The unwanted adverse effects of inhibiting apoptosis need to be carefully considered when pursuing novel targets and approaches for aortic aneurysm treatment.

**Necroptosis**

Necroptosis is another kind of programmed cell death. Unlike apoptosis, necroptosis does not involve caspases and usually induces local inflammation. Necroptosis has been implicated in atherosclerosis, ischemia-reperfusion injury and myocardial infarction. Receptor interacting serine/threonine kinase 1 (RIP1), RIP3, and mixed lineage kinase domain-like pseudokinase are the primary effectors of necroptosis. Increased necroptosis was found in both human and murine AAA. RIP1 inhibition with necrostatin-1 or Rip3 genetic deficiency protects mice from elastase-induced AAA. Consistently, the dual inhibitor of RIP1/RIP3, GSK2593074A, inhibits angiotensin II– and calcium-induced AAA in mice. These studies reveal the potential application of necroptosis inhibitors in treating aortic aneurysm.

**VSMC Senescence**

AAA incidence increases dramatically with advancing age, indicating AAA to be an aging-related pathological process. On the cellular level, features of VSMC senescence include DNA damage, telomere shortening, epigenetic changes, loss of proteostasis, abnormal nutrient sensing, and mitochondrial dysfunction. Current evidence shows that VSMC senescence is involved in aortic aneurysm development. The mammalian sirtuins (sirtuins1–7) are highly conserved deacetylases and promising targets for antiaging therapy. Age-related sirtuin1 was observed to be decreased in human AAA samples. VSMC-specific Sirt1 knockout and transgenic mice consistently show that sirtuin 1 significantly attenuates AAA formation via inhibition of the p21 and nuclear factor kappa B pathways in angiotensin II and CaCl₂ aortic aneurysm mouse models. Nicotinamide phosphoribosyltransferase and the nicotinamide adenine dinucleotide fueling system replenish the substrates used by sirtuin proteins. This system is impaired in the aorta from patients with dilated aortopathy, and VSMC-Nampt knockout mice show premature vascular senescence and dissection. These studies indicate that aged VSMCs are more susceptible to pathological stimuli, leading to an increased risk of aortic aneurysm in aging individuals.

**VSMC Autophagy**

Autophagy is an evolutionarily conserved process for cells to remove unwanted protein and organelles. Impaired autophagy in cells may lead to endoplasmic reticulum stress, inflammation, and even cell death. Enhanced autophagy in VSMCs shows protective effects on various vascular diseases, including vascular calcification, neointimal formation, and atherosclerosis. In response to increased ROS, cytokines, metabolic stress, or growth factors, autophagy is activated in VSMCs in aortic aneurysm. The importance of autophagy in maintaining VSMC homeostasis is further demonstrated by VSMC-specific knockout of autophagy machinery proteins. Deletion of autophagy related 5 (Atg5) in VSMCs increases the incidence of abdominal aortic dissection and promotes vascular inflammation in the angiotensin II aneurysm mouse model. Autophagy related 7 (Atg7) knockout in VSMCs exacerbates adverse cardiac remodeling and dissecting abdominal aortic aneurysm in mice after angiotensin II treatment.

Dysfunction and loss of VSMCs are common features in aortic aneurysm development. This section briefly summarizes our knowledge about VSMC phenotypical switching, inflammation, oxidative stress, death, senescence, and autophagy, and their roles in aneurysm development. Importantly, these different pathways are not separate from each other, or rather, there is often crosstalk and cell signal convergence of these pathways. For example, autophagy is closely related to senescence, as aging cells usually show impaired autophagy and defective autophagy results in accelerated senescence. Defective autophagy leads to enhanced VSMC phenotypic switching and cell death.

A deeper understanding of these complex pathways and their interactions is key to finding safe and efficient therapies for treating aortic aneurysm.

**CONCLUSIONS AND PERSPECTIVES**

The development of aortic aneurysm is a complex process involving multiple cell types. Beyond this, previously defined cell types such as VSMCs or macrophages also consist of several distinct subtypes. They may exert different roles in the initiation and progression of the disease. The recent application of single-cell RNA sequencing technology largely expanded our understanding of cellular heterogeneity. In aortas from elastase-induced AAA mice, at least 4 VSMC clusters and 5 monocyte/macrophage clusters were identified. Furthermore, human aortic aneurysm samples also show heterogeneity with different VSMC clusters (contractile, stressed, and proliferating). This heterogeneity must be taken into consideration when developing new drugs and approaches to avoid nonspecific adverse effects.
Aortic aneurysm remains a significant cause of death because of its high mortality once rupture takes place. Open surgery and endovascular repair remain the major treatments for aortic aneurysm. These procedures have specific limitations, including the feasibility of aortic aneurysm surgery for each patient and surgery-related complications. Unfortunately, no drugs to date have been shown to be effective in clinical trials, although novel diagnostic and therapeutic strategies are still under development. In both human and animal aortic aneurysms, VSMC phenotypic switching, inflammation, oxidative stress, cell death, autophagy, and senescence are involved in the development and progression of disease. Currently, many of the detailed mechanisms underlying aortic aneurysm still come from animal models. Each animal model has its advantages and pitfalls, and therefore it is always important to consider its relevance to human conditions and pathophysiology. Further studies are necessary to overcome these limitations for improved research translation and subsequent clinical application for treating aortic aneurysm.

ARTICLE INFORMATION

Affiliations
Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, MI (H.L., Y.E.C.); Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH (W.D., L.R., Y.F.); Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA (M.H.H.); and Division of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B., Y.F.).

Sources of Funding
The present work was supported by the National Institutes of Health (grant R01HL138094 and R01HL145176 to Dr Fan; R01HL088878, R01HL137214, and R01HL134569 to Dr Chen). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosures
None.

REFERENCES
1. Bossone E, Eagle KA. Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes. *Net Rev Cardiol*. 2021;18:331–348. doi: 10.1038/s41569-020-00472-6
2. Sampson UK, Norman PE, Fowkes FG, Aboyans V, Yanna S, Harrell FE Jr, Forouzanfar MH, Nagnhi M, Denenberg JO, McDermott MM, et al. Global and regional burden of aortic dissection and aneurysms: mortality trends in 21 world regions, 1990 to 2010. *Glob Heart*. 2014;9:171–180.e110.
3. Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. *Nat Rev Mol Cell Biol*. 2011;12:551–564. doi: 10.1038/nrm3176
4. Golledge J. Abdominal aortic aneurysm: update on pathogenesis and medical treatments. *Nat Rev Cardiol*. 2019;16:225–242. doi: 10.1038/s41569-018-0114-9
5. Pinard A, Jones GT, Milewicz DM. Genetics of thoracic and abdominal aortic diseases. *Circ Res*. 2019;124:588–606. doi: 10.1161/CIRCRESAHA.118.312436
6. Pilszgraff ER, Shelton EL, Galindo CL, Neims BL, Hooper OW, Poole SD, Labosky PA, Bader DM, Reese J. Embryonic domains of the aorta derived from diverse origins exhibit distinct properties that converge into a common phenotype in the adult. *J Mol Cell Cardiol*. 2014;69:88–96. doi: 10.1016/j.yjmcc.2014.01.016
7. Wang G, Jacquet L, Karamarit E, Xu Q. Origin and differentiation of vascular smooth muscle cells. *J Physiol*. 2015;593:3013–3030. doi: 10.1113/JP270033
8. Trigueros-Motos L, González-Granado JM, Cheung C, Fernández P, Sánchez-Cabo F, Dopaço A, Sinha S, Andrés V. Embryological- origin-dependent differences in homeobox expression in adult aorta: role in regional phenotypic variability and regulation of NF-κB activity. *Atheroscler Thromb Vasc Biol*. 2013;33:1248–1256. doi: 10.1161/ATVBAHA.112.300539
9. Shihaburama H, Olson JM, van Vlijmen-van Keulen C, Buxbaum SG, Dudek DM, Tromp G, Ogata T, Skurcda M, Sakalhainas N, Paul G, et al. Genome scan for familial abdominal aortic aneurysm using sex and family history as covariates suggests genetic heterogeneity and identifies linkage to chromosome 19q13. *Circulation*. 2004;109:2103–2108. doi: 10.1161/01.CIR.0000127857.77161.A1
10. Gretarsdottr S, Baas AF, Thorliefsson G, Holm H, den Heijer M, de Vries J-P, Kranendonk SE, Zeebregts CJAM, van Sterkenburg SM, Geelkerken RH, et al. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring risk of abdominal aortic aneurysm. *Nat Genet*. 2010;42:692–697. doi: 10.1038/ng.622
11. Jones GT, Tromp G, Kuivaniemi H, Gretarsdottr S, Baas AF, Giusti B, Strauss E, van’t Hof PNG, Webb TR, Erdman R, et al. Meta-analysis of genome-wide association studies for abdominal aortic aneurysm identifies four new disease-specific risk loci. *Circ Res*. 2017;120:341–353. doi: 10.1161/CIRCRESAHA.116.308765
12. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. *Nat Rev Drug Discov*. 2012;11:790–811. doi: 10.1038/nrd3810
13. Daugherty A, Chen Z, Sawada H, Rateri DL, Sheppard MB. Transforming growth factor-β in thoracic aortic aneurysms: good, bad, or irrelevant? *J Am Heart Assoc*. 2017;6:e005221. doi: 10.1161/JAHA.116.005221
14. Forester ND, Cruickshank SM, Scott DJ, Carding SR. Functional characterization of T cells in abdominal aortic aneurysms. *Immunology*. 2005;115:262–270. doi: 10.1111/j.1365-2567.2005.02157.x
15. Eliason JL, Hannawa KK, Aliajadi G, Sinha H, Ford JW, Deogracias MP, Roelfs KJ, Woodrum DT, Ennis TL, Henke PK, et al. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. *Circulation*. 2005;112:232–240. doi: 10.1161/CIRCULATIONAHA.104.517291
16. He Li, FuYL, Deng J, Shen Y, Wang Y, Yu F, Xie N, Chen Z, Hong T, Peng X, et al. Deficiency of FAM3D (family with sequence similarity 3, member D), a novel chemokine, attenuates neutrophil recruitment and ameliorates aortic aneurysm development. *Arterioscler Thromb Vasc Biol*. 2018;38:1616–1631. doi: 10.1161/ATVBAHA.118.311289
17. Tieu BC, Ju X, Lee C, Sun H, Lejeune W, Recinos A III, Brasier AR, Tithon RG. Aortic adventitial fibroblasts participate in angiotensin-induced vascular wall inflammation and remodeling. *J Vasc Res*. 2011;48:261–272. doi: 10.1159/000322038
18. Raffort J, Lareyre F, Clément M, Hassan-Khodja R, Chinetti G, Mallat Z. Monocytes and macrophages in abdominal aortic aneurysm. *Nat Rev Cardiol*. 2017;14:457–471. doi: 10.1038/nrccardio.2017.52
19. Pope NH, Salmon M, Johnston WP, Lu G, Lau OL, Upchurch GR Jr, Aliajadi G. Interleukin-6 receptor inhibition prevents descending thoracic aortic aneurysm formation. *Ann Thorac Surg*. 2015;100:1620–1626. doi: 10.1016/j.athoracsur.2015.05.009
20. Quintana RA, Taylor WR. Cellular mechanisms of aortic aneurysm formation. *Circ Res*. 2019;124:607–618. doi: 10.1161/CIRCRESAHA.118.313167
21. Janve S, Hu M, Shen M, Kassis Z, Extracellular matrix, regional heterogeneity of the aorta, and aortic aneurysm. *Exp Mol Med*. 2019;51:1–15. doi: 10.1038/s12276-019-0286-3
22. Mochizuki S, Brassart B, Hinek A. Signaling pathways transduced through the elastin receptor facilitate proliferation of arterial smooth muscle cells. *J Biol Chem*. 2002;277:44853–44863. doi: 10.1074/jbc.M205663200
23. Lin CJ, Lin CY, Stitzel NO. Genetics of the extracellular matrix in aortic aneurysmal diseases. *Matrix Biol*. 2018;71–72:128–143. doi: 10.1016/j.matbio.2018.04.005
24. Sèneaud J, Caliguri G, Etienne H, Debosc S, Michel JB, Coscas R. Translational relevance and recent advances of animal models of abdominal aortic aneurysm. *Arterioscler Thromb Vasc Biol*. 2017;37:401–410. doi: 10.1161/ATVBAHA.116.308534

Lu et al Role of VSMCs in Aortic Aneurysm

J Am Heart Assoc. 2021;10:e023601. DOI: 10.1161/JAHA.121.023601
24. Daugherty A, Manning MW, Cassia LS. Angiotensin II promotes ath erosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605–1612. doi: 10.1172/JCI7818

25. Lu H, Howatt DA, Balakrishnan M, Graham MJ, Mullick AE, Daugherty A. Hypercholesterolemia induced by a PCSK9 gain-of-function mutation augments angiotensin II-induced abdominal aortic aneurysms in C57BL/6J mice: brief report. Arterioscler Thromb Vasc Biol. 2016;36:1753–1757. doi: 10.1161/ATVBAHA.116.330760

26. Liu S, Xie Z, Daugherty A, Cassia LA, Pearson KJ, Gong MC, Guo Z. Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt. Arterioscler Thromb Vasc Biol. 2013;33:1568–1579. doi: 10.1161/ATVBAHA.113.300820

27. Pyo R, Lee JK, Shimley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Sharpio RD, Tiori RM, Thompson RW. Tamm-Horsfall protein dysregulation of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641–1649. doi: 10.1172/JCI9831

28. Bhamidipati CM, Mehta GS, Lu G, Moehle CW, Barbery C, DiMusto PD, Laser A, Kron IL, Upchurch GR Jr, Ailawadi G. Development of a novel murine model of aortic aneurysms using peri-adventitial elastase. Surgery. 2012;152:238–246. doi: 10.1016/j.surg.2012.02.010

29. Tyerman Z, Dahi J, Shannon A, Johnston WF, Pope NH, Lu G, Upchurch GR Jr, Ailawadi G, Salmon M. Murine surgical model of topical elastase induced descending thoracic aortic aneurysm. J Vis Exp. 2019. doi: 10.3791/61015

30. Patelis N, Moris D, Schizas D, Damaskos C, Perrea D, Bakoyiannis N, Liakakos T, Georgopoulos S. Analysis of the murine abdominal aorta in the development of atherosclerosis. Am J Physiol Heart Circ Physiol. 2010;299:H1285–H1301. doi: 10.1152/ajpheart.05998.2009

31. Chioff AC, Chia B, Pearce WH. Mouse aortic aneurysm produced by perinatal application of calcium chloride. J Surg Res. 2001;99:371–376. doi: 10.1006/jsre.2001.6207

32. Lee VS, Halabi CM, Hoffman EP, Carmichael N, Leshchiner I, Lian CG, Kanematsu Y, Kanematsu M, Kurihara C, Tsou TL, Nuki Y, Liang EI, Kanematsu M, Kurihara C, Tsou TL, Nuki Y, Liang EI. Aneurysm formation in the aorta of mice with angiotensin receptor type 1 (AT1) deficiency. Mo sa J Med Sci. 2010;324:117–120. doi: 10.1016/j.aphs.2007.08.088

33. Petrozza AJ, Tashima Y, Shad R, Cheng P, Wirka R, Churovich S, Malagon-Lopez J, Wang Z, Bergaya S, Gujja S, Ailawadi G, Murtaida S-I, Zhang X, et al. Smooth muscle cell reprogramming in aortic aneurysms. Cell Stem Cell. 2020;26:542–557.e51. doi: 10.1016/j.stem.2020.02.013

34. Zeng T, Shi L, Qi Q, Shi Y, Huang Y, Liu YJ, Gan J, Yuan J, Lu Z, Xue Y, et al. Cytokines in aortic dissection. Clin Chim Acta. 2015;450:25–32. doi: 10.1016/j.cca.2015.06.028

35. Wu QY, Cheng Z, Zhou YZ, Zhao Y, Li JM, Peng HL, Zhang GS, Xiao L. A novel STAT3 inhibitor attenuates angiotensin II-induced smooth muscle cell apoptosis and autophagy in dissecting aortic aneurysms. Vascular. 2015;23:148–156. doi: 10.1177/1939027715597778

36. Lee VS, Halabi CM, Hoffman EP, Carmichael N, Leshchiner I, Lian CG, Kanematsu Y, Kanematsu M, Kurihara C, Tsou TL, Nuki Y, Liang EI, Kanematsu M, Kurihara C, Tsou TL, Nuki Y, Liang EI. Aneurysm formation in the aorta of mice with angiotensin receptor type 1 (AT1) deficiency. Mo sa J Med Sci. 2010;324:117–120. doi: 10.1016/j.aphs.2007.08.088

37. Petrozza AJ, Tashima Y, Shad R, Cheng P, Wirka R, Churovich S, Malagon-Lopez J, Wang Z, Bergaya S, Gujja S, Ailawadi G, Murtaida S-I, Zhang X, et al. Smooth muscle cell reprogramming in aortic aneurysms. Cell Stem Cell. 2020;26:542–557.e51. doi: 10.1016/j.stem.2020.02.013
The role of VSMCs in aortic aneurysms.

Lu et al. 2021. J Am Heart Assoc. 2021;10:e023601. DOI: 10.1161/JAHA.121.023601

Role of VSMCs in Aortic Aneurysm

DHW, et al. Decreased mitochondrial respiration in aeurysmal aortas of Fblun-4 mutant mice is linked to PG1C1a regulation. Cardiovasc Res. 2018;114:1776–1793. doi: 10.1093/cvr/cvy150

Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175–193. doi: 10.1038/s41580-018-0089-8

Hsieh CC, Yen MH, Yen CH, Lau YT. Oxidized low density lipoprotein induces apoptosis via generation of reactive oxygen species in vascular smooth muscle cells. Cardiovasc Res. 2001;49:135–145. doi: 10.1016/S0008-6369(00)02182-8

Pedrozzi AJ, Koyano T, Trojan J, Rubin A, Palmon I, Jastinen K, Burdon G, Chang P, Tashima Y, Cui JZ, et al. Divergent effects of canonical and non-canonical TGF-β signaling on mixed contractile-synthetic smooth muscle cell phenotypes in human Marfan syndrome aortic root aneurysms. J Cell Mol Med. 2020;24:2369–2385. doi: 10.1111/jcmm.14921

Granata A, Serrano F, Bernard WG, McNamara M, Low L, Sastry P, Sinha S. An IPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death. Nat Genet. 2017;49:97–108. doi: 10.1038/ng.3723

Lu H, Sun J, Liang W, Chang Z, Rom O, Zhao Y, Zhao G, Xiong W, Wang H, Zhu T, et al. Cyclohexrin prevents abdominal aortic aneurysm via activation of vascular smooth muscle cell transcription factor EB. Circulation. 2020;142:483–498. doi: 10.1161/CIRCULATIONAHA.119.044803

Lai CH, Chang OW, Lee FT, Kuo CH, Hsu JH, Liu CP, Wu HL, Yeh JL. Targeting vascular smooth muscle cell dysfunction with xanthine derivative MIPU-3 inhibits abdominal aortic aneurysms in mice. Atherosclerosis. 2020;297:24–34. doi: 10.1016/j.atherosclerosis.2020.01.029

Lepper NJ, Raiesdana A, Kojima Y, Kundu RK, Cheng H, Maeggedfessel L, Toh R, Ahn GO, Ali ZA, Anderson DR, et al. Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler Thromb Vasc Biol. 2013;33:e1–e10.

Wang W, Shen M, Fischer C, Basu R, Hjerrild S, Couvmeau P, Paul M, Wang F, Toth S, Mix DS, et al. Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs. Proc Natl Acad Sci USA. 2019;116:13006–13015. doi: 10.1073/pnas.1900152116

Yamanouchi D, Morgan S, Kato K, Lengfeld J, Zhang F, Liu B. Effects of caspase inhibitor on angiotensin II-induced abdominal aortic aneurysm in apoliprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2013;33:e1–e10.

Wang Q, Liu Z, Ren J, Morgan S, Assa C, Liu B. Receptor-interacting protein kinase 3 contributes to abdominal aortic aneurysms via smooth muscle cell necrosis and inflammation. Circ Res. 2015;116:600–611. doi: 10.1161/CIRCRESAHA.115.304908

Wang Q, Zhou T, Liu Z, Ren J, Phan N, Gupta K, Stewart DM, Morgan S, Assa C, Kent KC, et al. Inhibition of receptor-interacting protein kinase 1 with necrostatin-1 ameliorates disease progression in elastase-induced mouse abdominal aortic aneurysm model. Sci Rep. 2017;7:42159. doi: 10.1038/srep42159

Khoury MK, Zhou T, Yang H, Prince SR, Gupta K, Stanstr A, Wang Q, Liu B, GSK2593074A blocks progression of existing abdominal aortic dilation. JVS Sci. 2020;1:123–135. doi: 10.1016/j.jvssci.2020.07.001

Zhou T, Wang Q, Phan N, Ren J, Yang H, Feldman CC, Feiltenberger JB, Ye Z, Willdman SA, Tang W, et al. Identification of a novel class of RPI/RPS dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models. Cell Death Dis. 2019;10:226. doi: 10.1038/s41419-019-1468-6

Urga AK, Bennett MR. Ageing induced vascular smooth muscle cell senescence in atherosclerosis. J Physiol. 2016;594:2115–2124. doi: 10.1113/jphysiol.2015.326400

Chen H-Z, Wang F, Gao P, Pei J-F, Liu Y, Xu T-T, Tang X, Fu W-Y, Lu J, Yan Y-F, et al. Age-associated sirtuin 1 reduction in vascular smooth muscle linked to vascular senescence and inflammation to abdominal aortic aneurysm. Circ Res. 2016;119:1078–1088. doi: 10.1161/CIRCRESAHA.116.308895

Grabowska W, Sikora E, Bielak-Zmijewska A, Sirtuins, a promising target in slowing down the ageing process. Biogerontology. 2017;18:447–476. doi: 10.1007/s10522-017-9685-9

Watson A, Nong Z, Yin H, Cao F, Xiong S, Saito B, Guo L, Lioo O, Chu MWA, Gros R, et al. Nicotinamide phosphoribosyltransferase in smooth
muscle cells maintains genome integrity, resists aortic medial degenera-
tion, and is suppressed in human thoracic aortic aneurysm disease. Circ 
Res. 2017;120:1889–1902. doi: 10.1161/CIRCRESAHA.116.310022
94. Osonoi Y, Mita T, Azuma K, Nakajima K, Masuyama A, Goto H, Nishida
Y, Miyatsuka T, Fujitani Y, Koike M, et al. Defective autophagy in vas-
cular smooth muscle cells enhances cell death and atherosclerosis. 
Autophagy. 2018;14:1991–2006. doi: 10.1080/15548627.2018.1501132
95. Phadwal K, Feng D, Zhu D, MacRae VE. Autophagy as a novel therapeu-
tic target in vascular calcification. Pharmacol Ther. 2020;206:107430. 
doi: 10.1016/j.pharmthera.2019.107430
96. Grootaert MO, da Costa Martins PA, Bitsch N, Pintelon I, De Meyer
GR, Martinet W, Schrijvers DM. Defective autophagy in vascular 
smooth muscle cells accelerates senescence and promotes neoin-
tima formation and atherogenesis. Autophagy. 2015;11:2014–2032. 
doi: 10.1080/15548627.2015.1096485
97. Ramadan A, Singh KK, Quan A, Plant PJ, Al-Omran M, Tech H, Verma
S. Loss of vascular smooth muscle cell autophagy exacerbates angio-
tensin II-associated aortic remodeling. J Vasc Surg. 2018;68:859–871. 
doi: 10.1016/j.jvs.2017.08.086
98. Herranz N, Gil J. Mechanisms and functions of cellular senescence. J 
Clin Invest. 2018;128:1238–1246. doi: 10.1172/JCI95148
99. Zhao G, Lu H, Chang Z, Zhao Y, Zhu T, Chang L, Guo Y, Garcia-Barrio
MT, Chen YE, Zhang J. Single-cell RNA sequencing reveals the cellular 
heterogeneity of aneurysmal infrarenal abdominal aorta. Cardiovasc 
Res. 2021;117:1402–1416. doi: 10.1093/cvr/cvaa214
100. Li Y, Ren P, Dawson A, Vasquez HG, Ageedi W, Zhang C, Luo W, Chen
R, Li Y, Kim S, et al. Single-cell transcriptome analysis reveals dynamic 
cell populations and differential gene expression patterns in control 
and aneurysmal human aortic tissue. Circulation. 2020;142:1374– 
1388. doi: 10.1161/CIRCULATIONAHA.120.046528